Connect with us
Rovi announced that it estimates its operating income will decrease by around 10% compared to 2023. This forecast has been justified, mainly, by the fact that...
Rovi obtained a gross operating result of €279 million in 2022. Sales of the heparin division increased by 9% in 2022 compared to 2021, up to...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...